Evidence map›Paper›PMID 40216662›Full record

ArticleMammalian genome : official journal of the International Mammalian Genome Society2025

TCR CDR3 chemical complementarity to HPV epitopes is associated with a better outcome for cervical cancer.

Deo Rei L Agnila, Rahul Jain, Michael J Diaz, Tabitha R Hudlock, Rachel A Eakins, Andrea Chobrutskiy, Boris I Chobrutskiy, George Blanck

Abstract read
PubMed Publisher
In one paragraph

Article in Mammalian genome : official journal of the International Mammalian Genome Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Deo Rei L AgnilaDepartment of Molecular Medicine, Morsani College of Medicine, University of South Florida, Tampa, FL, 33612, USA.
Rahul JainDepartment of Molecular Medicine, Morsani College of Medicine, University of South Florida, Tampa, FL, 33612, USA.
Michael J DiazDepartment of Molecular Medicine, Morsani College of Medicine, University of South Florida, Tampa, FL, 33612, USA.
Tabitha R HudlockDepartment of Molecular Medicine, Morsani College of Medicine, University of South Florida, Tampa, FL, 33612, USA.
Rachel A EakinsDepartment of Molecular Medicine, Morsani College of Medicine, University of South Florida, Tampa, FL, 33612, USA.
Andrea ChobrutskiyDepartment of Pediatrics, Oregon Health and Science University Hospital, Portland, OR, 97239, USA.
Boris I ChobrutskiyDepartment of Internal Medicine, Oregon Health and Science University Hospital, Portland, OR, 97239, USA.
George BlanckDepartment of Molecular Medicine, Morsani College of Medicine, University of South Florida, Tampa, FL, 33612, USA. gblanck@usf.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite the fact that HPV vaccines are likely to lead to a significant reduction in cervical cancer occurrence, there remains cervical cancer incidence independent of the vaccine and cervical cancer arising in the absence of vaccination. Thus, continued efforts are needed to address the potential parameters of cervical cancer that could impact therapy and could lead to additional ways of reducing cervical cancer death rates. Adaptive immune receptor recombinations were obtained from the cancer genome atlas (TCGA) cervical cancer database through tumor exome and RNAseq files as well as from the independent Cancer Genome Characterization Initiative (CGCI) cervical cancer dataset. T-cell receptor (TCR) complementarity determining region-3's (CDR3s) were then assessed, based on chemical complementarity to human papillomavirus (HPV) T-cell epitopes. Results indicated increased overall survival probabilities consistently across the three TCR datasets with TCR CDR3 chemical complementarity to the same HPV epitopes, specifically immune epitope database (IEDB) designations: IEDB-1625373, IEDB-174148, and IEDB-110943. Among other potential applications of these results, the results may indicate HPV epitopes that could be useful targets for immunotherapy.

Indexed as

Complementarity Determining RegionsEpitopes, T-LymphocytePapillomaviridaePapillomavirus InfectionsReceptors, Antigen, T-CellUterine Cervical NeoplasmsFemaleHumansComplementarity Determining RegionsEpitopes, T-LymphocyteReceptors, Antigen, T-CellAdaptivematch.comCDR3-epitope chemical complementarityCervical cancerHPVT-cell receptors

Identifiers

PMID40216662

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.